Leptomeningeal enhancement under different MS immunotherapies: A monocentric retrospective cohort study of 214 patients.

Friedli, Christoph; Wagner, Franca; Hammer, Helly Noemi; Kamber, Nicole; Wiest, Roland; Diem, Lara; Chan, Andrew; Salmen, Anke; Hoepner, Robert (2023). Leptomeningeal enhancement under different MS immunotherapies: A monocentric retrospective cohort study of 214 patients. Multiple sclerosis journal, 29(1), pp. 63-73. Sage 10.1177/13524585221122210

Full text not available from this repository. (Request a copy)

BACKGROUND

Leptomeningeal inflammation in patients with multiple sclerosis (MS) mainly affects meningeal B-cell follicle-like structures linked to cortical and subpial lesions and can be visualized as leptomeningeal enhancement (LME).

OBJECTIVE

To evaluate the evolution of LME under different MS immunotherapies.

METHODS

A total of 214 MS patients treated with anti-CD20 therapies or fingolimod at the university hospital Bern were screened for LME. Magnetic resonance imaging (MRI) and medical records were retrospectively evaluated, and comparative statistics were applied.

RESULTS

We compared MS patients treated with anti-CD20 therapies (128 patients (59.8%)) or fingolimod (86 patients (40.2%)). Of 128 anti-CD20-treated patients, 108 (84.4%) had no LME, 11 (8.6%) had persistent LME, and 9 (7.0%) showed resolution of LME. Of 86 fingolimod-treated MS patients, 81 (94.2%) had no LME and 5 (5.8%) persistent LME. Patients with LME persistence were older than those without or resolution of LME (p = 0.039). Resolution of LME was more frequent during anti-CD20 compared with fingolimod treatment (p = 0.019).

CONCLUSION

We observed LME resolution under treatment with anti-CD20 therapies. As LME might play an important role in cerebral gray matter pathology in MS, further investigations including extensions to higher field strengths, correlation with clinical phenotypes, and comparison with other immunotherapies are needed.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology
04 Faculty of Medicine > Department of Radiology, Neuroradiology and Nuclear Medicine (DRNN) > Institute of Diagnostic and Interventional Neuroradiology

UniBE Contributor:

Friedli, Christoph Daniel, Wagner, Franca, Hammer, Helly Noemi, Kamber, Nicole, Wiest, Roland Gerhard Rudi, Diem, Lara, Chan, Andrew Hao-Kuang, Salmen, Anke, Hoepner, Robert

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1352-4585

Publisher:

Sage

Language:

English

Submitter:

Pubmed Import

Date Deposited:

20 Sep 2022 15:15

Last Modified:

30 Jan 2023 00:12

Publisher DOI:

10.1177/13524585221122210

PubMed ID:

36113094

Uncontrolled Keywords:

LME MRI Multiple sclerosis biomarker immunotherapy

URI:

https://boris.unibe.ch/id/eprint/173039

Actions (login required)

Edit item Edit item
Provide Feedback